As of September 18, 2026, VIJAYA's technical stance is primarily bullish, with the current price of ₹1558.9 trading above key moving averages across daily, weekly, and monthly timeframes. This alignment suggests a consistent upward trend across multiple periods. The daily trend shows a strong bullish SuperTrend at ₹1381.61, with the price well above the 200-day Simple Moving Average (SMA) of ₹1173.37. Weekly and monthly timeframes also exhibit bullish SuperTrends at ₹1214.27 and ₹882.74 respectively, reinforcing the positive outlook. The stock is trading near its recent highs, with the nearest resistance level identified at ₹1573.03, approximately 0.91% above the current price. Key support is noted at ₹1539.57, about 1.24% below the current price. The stock has experienced a recent upward gap on September 17, 2026, indicating positive momentum. However, the presence of a "Hammer" pattern on the monthly timeframe, which can sometimes signal a reversal, warrants attention. The annualized volatility stands at 41%, and the Average True Range (ATR) is 3.59% of the price, indicating moderate risk.

Key watch conditions include monitoring the price action around the nearest resistance level of ₹1573.03. A sustained move above this level could signal further upside. Conversely, a break below the support at ₹1539.57, especially on increased volume, might indicate a short-term pullback. The recent "upward_gap" anomaly on September 17, 2026, suggests immediate buying interest, but the "Hammer" pattern on the monthly chart suggests caution regarding potential consolidation or reversal.

Vijaya Diagnostic Centre is scheduled to trade ex-dividend on September 16, 2026. This means that investors purchasing the stock on or after this date will not be eligible to receive the upcoming dividend payout. Separately, brokerages anticipate that the diagnostics sector, including companies like Vijaya Diagnostic Centre, will experience sustained volume growth through fiscal year 2027. This positive outlook is attributed to stable pricing strategies, robust consumer demand (B2C), and the benefits of operating leverage.

As of September 18, 2026, Vijaya Diagnostic Centre's share price has seen an increase to ₹1558.9 from its previous price of ₹1506.1. This marks a recent upward movement in the stock's valuation. No new filings or news developments were reported in the period leading up to this observation date. The company continues its operations on the NSE, with no changes noted in its fundamental context.

Vijaya Diagnostic Centre Limited has announced a dividend of ₹2 per share, with a record date of September 16, 2026. This distribution returns capital to shareholders. In a separate development, the company has approved the execution of a Business Transfer Agreement (BTA) for the 100% acquisition of the integrated diagnostic business of Arya Wellness Centre in Guwahati, Assam. This acquisition is structured as a slump sale and is subject to certain conditions precedent. The transaction consideration is approximately ₹46 crore, based on an adjusted FY26 EBITDA valuation of 8-9x. Arya Wellness Centre reported FY26 revenue from operations of ₹260 million, with an EBITDA of ₹56 million and a Profit After Tax (PAT) of ₹25 million. The acquisition is anticipated to be completed around November/December 2026. Additionally, the company appointed Dr. Venkata Naresh Yallapragada as Chief Information Officer (CIO) on September 2, 2026, bringing over 23 years of experience in Healthcare IT leadership.

Vijaya Diagnostic Centre reported a consistent upward trend in its revenue from operations over the observed periods. Revenue grew from ₹205.21 crore in Q3 FY2025-26 to ₹230.98 crore in Q1 FY2026-27. This top-line growth was accompanied by an increase in Profit Before Tax, which rose from ₹58.22 crore in Q3 FY2025-26 to ₹70.94 crore in Q1 FY2026-27. The company's Profit Loss for the Period also showed a positive trajectory, increasing from ₹43.18 crore in Q3 FY2025-26 to ₹53.10 crore in Q1 FY2026-27. While revenue and profit have grown, Finance Costs have also increased, from ₹8.59 crore in Q3 FY2025-26 to ₹11 crore in Q1 FY2026-27, indicating a rise in borrowing costs or debt levels. Other Expenses have also seen a sequential increase. The Tax Expense has moved in line with Profit Before Tax.

Key monitoring areas include the sustained growth in revenue and profitability, and the management of increasing finance costs and other operating expenses. Investors should observe how the company's revenue growth translates into operating leverage and impacts its net profit margins amidst rising costs.

Vijaya Diagnostic Centre's stock shows a constructive technical setup across multiple timeframes. The daily, weekly, and monthly trends are all indicated as bullish, with the Supertrend indicator suggesting upward momentum. This is further supported by positive returns over various periods, including a significant 66% return over the last six months and a 50% year-to-date return. The stock is trading above its 20-day, 50-day, and 200-day Simple Moving Averages (SMAs) and Exponential Moving Averages (EMAs), indicating short-to-medium term strength. Nearest resistance levels are observed around ₹1573.03 and ₹1575.5, while support is identified near ₹1539.57.

While the diagnostics sector generally shows robust demand and pricing power, specific company performance may face constraints. The company's stock has experienced significant price appreciation over the past year, with a year-to-date return of 0.5 and a 6-month return of 0.66. However, the current price is trading near a resistance level, with the nearest identified resistance at ₹1573.03, which is 0.91% above the current price. The stock also exhibits notable volatility, with an annualized volatility of 0.41 and a maximum drawdown of -0.31 observed historically. The Average True Range (ATR) as a percentage of the price is 3.59, indicating potential for significant price swings.